Reports that the Seattle, Washington-based Immunex Corp. initiated a patient enrollment program to increase year-end sales of its anti-inflammatory drug Enbrel in November 2000. Purpose behind the company's initiative; Conditions imposed by the company on patients in order to use the drug further; Expected sales of the drug due to the program.